Premium
Follicular lymphoma: 2011 update on diagnosis and management
Author(s) -
Freedman Arnold
Publication year - 2011
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.22099
Subject(s) - follicular lymphoma , medicine , rituximab , lymphoma , b symptoms , gastroenterology , asymptomatic , cd20 , international prognostic index , lymph node biopsy , biopsy , lymph node , bone marrow , pathology , oncology
Disease overview: Follicular lymphoma (FL) is generally an indolent B‐cell lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by diffuse lymphoadenopathy, bone marrow involvement, splenomegaly, and less commonly other extranodal sites of involvement. In general, cytopenias can occur but constitutional symptoms of fever, nightsweats, and weight loss are uncommon. Diagnosis: Diagnosis is based on histology of preferably biopsy of a lymph node. Immunohistochemical staining is positive in virtually all cases for cell surface CD19, CD20, CD10 and monoclonal immunoglobulin, as well as cytoplasmic expression of bcl‐2 protein. The overwhelming majority of cases have the characteristic t(14;18) translocation involving the IgH/bcl‐2 genes. Risk stratification: The Follicular Lymphoma International Prognostic Index prognostic model for FL uses five independent predictors of inferior survival: age > 60 years, hemoglobin <12 g/dL, serum LDH > normal, Ann Arbor stage III/IV, number of involved nodal areas > 4. The presence of 0–1, 2, and ≥3 adverse factors defines low, intermediate, and high‐risk disease with median 10 year survivals in the pre‐rituximab era of approximately 71, 51, and 36 months, respectively. With the use of more modern therapies, specifically anti‐CD20 monoclonal antibody, the outcome has improved. Risk‐adapted therapy: Observation continues to be adequate for asymptomatic patients with low bulk disease and no cytopenias. For patients needing therapy, most patients are treated with chemotherapy plus rituximab, which has improved response rates, duration of response, and overall survival. Randomized studies have shown additional benefit for maintenance rituximab both following chemotherapy‐rituximab and single agent rituximab. Autologous stem cell transplantation has not shown a survival benefit in first remission patients. Stem cell transplantation (SCT) including both autologous and allogeneic SCT or experimental agent therapy is considered for recurrent disease. Am. J. Hematol. 86:769‐775, 2011. © 2011 Wiley‐Liss, Inc.